Business Overview: Illumina, Inc. (NASDAQ: ILMN)

---

Executive Summary

Illumina, Inc. is the world's leading developer and manufacturer of next-generation sequencing (NGS) and DNA microarray systems used to analyze genetic variation and biological function. Founded in 1998 and headquartered in San Diego, California, Illumina sells the sequencing instruments, consumables, and software that underpin most of the world's genomic research, clinical diagnostics, and agricultural/biotech applications.

Illumina generated $4.37 billion in revenue in fiscal 2024, built on a classic "razor-and-blade" model: it places sequencing instruments (the "razors") with research institutions, hospitals, and biotech/pharma companies, then earns durable, high-margin recurring revenue from the proprietary reagents and consumables (the "blades") those instruments consume on every run. Its installed base and consumables pull-through — not any single instrument sale — are what matter most to the business. The company spun off its early-cancer-detection unit GRAIL on June 24, 2024, and now reports as a single segment, Core Illumina, focused on sequencing and array platforms.

---

1. Core Business Model & How They Work

Illumina's economics follow a straightforward installed-base/consumables flywheel:

[ Instrument Sale/Placement ] ➡️ [ Growing Installed Base ] ➡️ [ Recurring Consumables Revenue per Run ] ➡️ [ Software/Informatics Lock-in ] ➡️ [ New Applications & Higher-Throughput Upgrades ]

Key Operational Drivers

1. Consumables-Driven Revenue Mix: Consumables (reagents, flow cells, library-prep kits) made up 72% of 2024 revenue; services were 16% and instruments just 12%. Sequencing alone accounted for 91% of total revenue, with arrays the remaining 9%.
2. Heavy, Sustained R&D Investment: Illumina spent $1,169 million on R&D in 2024 (26.7% of revenue) — among the highest R&D intensities in life-science tools — to keep its chemistry and instrument throughput ahead of long-read and lower-cost challengers.
3. Platform Breadth Across Throughput Tiers: The NovaSeq X Plus (launched 2023) serves high-throughput production sequencing (population genomics, large biobanks), while the MiSeq i100 series (launched 2024) targets benchtop/low-throughput labs — letting Illumina capture a customer from first benchtop purchase through enterprise-scale deployment.
4. Global Commercial & Clinical Reach: International shipments were $2.08 billion, or 48% of 2024 revenue, reflecting a worldwide base of academic, pharma/biotech, and commercial diagnostic-lab customers.

---

2. Product Portfolio

---

3. Competitive Landscape

Illumina faces competition that varies sharply by sequencing read-length and price tier.

          SEQUENCING COMPETITIVE MATRIX
┌────────────────────────────────────────────────────┐
│ High   ▲                                            │
│  T     │         [ILLUMINA]                         │
│  H     │      (Short-read scale leader)              │
│  R     │                        [Thermo Fisher]      │
│  O     │                     (Ion Torrent/broad tools)│
│  U     │  [PacBio]                                   │
│  G     │  (Long-read, HiFi accuracy) [Oxford Nanopore]│
│  H     │                              (Long-read,     │
│  P     │                               portable)      │
│  U     │                                              │
│  T     Low                                           │
│        └──────────────────────────────────────────► │
│          Low      READ LENGTH / PORTABILITY    High  │
└────────────────────────────────────────────────────┘

• Short-read NGS: Thermo Fisher Scientific (Ion Torrent and broader life-science tools) is the closest large diversified competitor, though Illumina retains the dominant global share of short-read sequencing output.
• Long-read sequencing: Pacific Biosciences (PacBio) and Oxford Nanopore Technologies compete for applications needing long reads or field-portable sequencing; Illumina has historically countered through internal long-read R&D investment and bolt-on technology deals rather than ceding the segment.
• Arrays & genotyping: Thermo Fisher, QIAGEN, and regional genomics players compete in population genotyping and agrigenomics array work.
• Clinical diagnostics adjacency: Roche and BGI are large, well-capitalized competitors in sequencing-adjacent diagnostics and, in BGI's case, lower-cost sequencing hardware in some international markets. The 10-K notes some competitors now also bring greater AI/software resources to bear on genomic analysis.

---

4. Strategic Strengths & Risks

Competitive Strengths (The Moat)

• Installed-base consumables lock-in: With ~91% of revenue from sequencing and a dominant global installed base, Illumina earns highly recurring, high-margin consumables revenue on every run performed on its platforms.
• Chemistry and workflow switching costs: Labs validate assays, LIMS integrations, and regulatory submissions (in clinical settings) around Illumina's specific chemistry; switching sequencing platforms requires re-validating protocols, a real and costly barrier.
• Scale-driven R&D reinvestment: Spending ~27% of revenue on R&D lets Illumina defend its lead across throughput tiers simultaneously (NovaSeq X Plus at the high end, MiSeq i100 at the low end) in a way smaller long-read specialists cannot match.

Strategic Risks & Vulnerabilities

1. Long-read Encroachment: PacBio and Oxford Nanopore continue to close the accuracy/cost gap in long-read sequencing, a segment better suited to structural-variant and complex-genome work that short-read platforms handle less well.
2. Post-GRAIL Strategic Reset: The June 2024 GRAIL spin-off refocuses Illumina on Core Illumina, removing a high-growth (but cash-burning) diagnostics optionality and leaving sequencing/arrays as the sole growth engine.
3. Pricing & Reimbursement Pressure: As genomic sequencing commoditizes at the low end and research/biopharma funding cycles fluctuate, consumables pricing faces pressure from both direct competitors and customers' own budget cycles.
4. Geopolitical/Trade Exposure: With 48% of revenue from international shipments, Illumina is exposed to export-control, tariff, and China-market-access risk affecting life-science tools broadly.

---

5. Financial Overview

---

6. Summary Conclusion

Illumina's business is, at its core, an installed-base consumables franchise: once a lab adopts an Illumina sequencer, the recurring, high-margin reagent and consumables revenue that follows is durable and difficult to displace without a costly platform switch. Having shed GRAIL, the company is now a cleaner, single-segment bet on defending and extending its share of the sequencing market across both the high-throughput (NovaSeq X Plus) and benchtop (MiSeq i100) tiers.

The biggest forward risk is technological: long-read specialists like PacBio and Oxford Nanopore are steadily narrowing the cost and accuracy gap in applications where short-read sequencing is weakest, while diversified giants like Thermo Fisher compete on breadth. Illumina's ~27%-of-revenue R&D reinvestment is the mechanism by which it intends to keep its installed-base moat ahead of both threats simultaneously.